The Oklahoma Rheumatic Diseases Research Cores Center (ORDRCC) currently supports rheumatic disease research for 32 junior ORDRCC investigators (some from outside Oklahoma) and 16 senior Center Investigators. Through the Clinical Characterization and Biorepository, the ORDRCC provides clinically well characterized patient resources for adult and pediatric systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, anti-phospholipid antibody syndrome and other diseases to our ORDRCC investigators. Additionally, ORDRCC investigators have access to cutting-edge technologies through our multi-disciplinary Phenotyping Core, which provides services in genetics, genomics, proteomics and immune phenotype/immune function assessment. The Administrative and Enrichment Core facilitates scientific advances and fosters multi-disciplinary interactions. Through implementation of these ORDRCC resources and activities, over the past funding cycle our rheumatic disease publications have doubled, our rheumatic disease publications including multiple ORDRCC investigators have tripled and rheumatic disease publications with other outside investigators have more than quadrupled. Along with this increase in collaborative, multidisciplinary rheumatic disease projects, our NIH funding has doubled, including several new multi-investigator grants which evolved out of ORDRCC interactions, including the Oklahoma Autoimmunity Center of Excellence and Center of Research Translational in Sjogren's. Eight of our junior investigators have graduated to Center status after receiving their initial independent NIH funding. Capitalizing on the scientific strengths of our ORDRCC Investigators, the overarching goals of our ORDRCC are to 1) integrate a multidisciplinary group of basic scientists and clinical investigators to study fundamental aspects of rheumatic disease, 2) fortify and expand this nucleus through directed recruitments, common educational forums, annual investigator meetings and collaborative scientific interactions, 3) offer access to critical, well-phenotyped clinical rheumatic disease collections, facilitating rheumatic disease research throughout the US, 4) implement access to centralized cutting-edge technologies to facilitate their rheumatic disease research and 5) provide the administrative, financial, and technical foundation to Oklahoma RDRCC investigators to accelerate their progress in understanding the etiology, pathogenesis, and management of rheumatic disease through multidisciplinary approaches.

Public Health Relevance

The Oklahoma Rheumatic Disease Research Cores Center facilitates, supports and expands multidisciplinary rheumatic disease research through developing junior investigators, attracting new talent to rheumatic disease research, participating in diverse Enrichment activities, supporting pilot projects, providing well-phenotyped samples to ORDRCC investigators for their individual studies and identifying, developing and applying new methodologies and technologies to facilitate rheumatic disease discoveries.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-08
Application #
8734206
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Wang, Yan Z
Project Start
2006-03-01
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
$672,000
Indirect Cost
$272,000
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113
LaBryer, Lauren; Sharma, Rohan; Chaudhari, Kaustubh Suresh et al. (2018) Kratom, an Emerging Drug of Abuse, Raises Prolactin and Causes Secondary Hypogonadism: Case Report. J Investig Med High Impact Case Rep 6:2324709618765022
Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962
Karp, David R; Chong, Benjamin F; James, Judith A et al. (2018) Mock Recruitment for the Study of Antimalarials in Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken) :
Pelikan, Richard C; Kelly, Jennifer A; Fu, Yao et al. (2018) Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9:2905
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531

Showing the most recent 10 out of 284 publications